Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

[Display omitted] •Fatty liver disease is a growing cause of cirrhosis and liver cancer globally.•Disease burden is expected to increase with the epidemics of obesity and diabetes.•Modeling shows slow growth in total cases and greater increase in advanced cases.•Mortality and advanced liver disease...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2018-10, Vol.69 (4), p.896-904
Hauptverfasser: Estes, Chris, Anstee, Quentin M., Arias-Loste, Maria Teresa, Bantel, Heike, Bellentani, Stefano, Caballeria, Joan, Colombo, Massimo, Craxi, Antonio, Crespo, Javier, Day, Christopher P., Eguchi, Yuichiro, Geier, Andreas, Kondili, Loreta A., Kroy, Daniela C., Lazarus, Jeffrey V., Loomba, Rohit, Manns, Michael P., Marchesini, Giulio, Nakajima, Atsushi, Negro, Francesco, Petta, Salvatore, Ratziu, Vlad, Romero-Gomez, Manuel, Sanyal, Arun, Schattenberg, Jörn M., Tacke, Frank, Tanaka, Junko, Trautwein, Christian, Wei, Lai, Zeuzem, Stefan, Razavi, Homie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 904
container_issue 4
container_start_page 896
container_title Journal of hepatology
container_volume 69
creator Estes, Chris
Anstee, Quentin M.
Arias-Loste, Maria Teresa
Bantel, Heike
Bellentani, Stefano
Caballeria, Joan
Colombo, Massimo
Craxi, Antonio
Crespo, Javier
Day, Christopher P.
Eguchi, Yuichiro
Geier, Andreas
Kondili, Loreta A.
Kroy, Daniela C.
Lazarus, Jeffrey V.
Loomba, Rohit
Manns, Michael P.
Marchesini, Giulio
Nakajima, Atsushi
Negro, Francesco
Petta, Salvatore
Ratziu, Vlad
Romero-Gomez, Manuel
Sanyal, Arun
Schattenberg, Jörn M.
Tacke, Frank
Tanaka, Junko
Trautwein, Christian
Wei, Lai
Zeuzem, Stefan
Razavi, Homie
description [Display omitted] •Fatty liver disease is a growing cause of cirrhosis and liver cancer globally.•Disease burden is expected to increase with the epidemics of obesity and diabetes.•Modeling shows slow growth in total cases and greater increase in advanced cases.•Mortality and advanced liver disease will more than double during 2016–2030. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.
doi_str_mv 10.1016/j.jhep.2018.05.036
format Article
fullrecord <record><control><sourceid>proquest_csuc_</sourceid><recordid>TN_cdi_csuc_recercat_oai_recercat_cat_2072_357019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827818321214</els_id><sourcerecordid>2131831529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-eb94483966fce5f91783a635635db61f3a03a47f64373c63b790352a8f24dccb3</originalsourceid><addsrcrecordid>eNp9Ub2O1DAYjBCIWw5egAJZoqFIgn8Sx5FoTgt7HCxQHFdbjv2FdZQ4wU6QrqOm5Q15EhztHkgUSLZGnzUzms-TJE8Jzgkm_GWXdweYcoqJyHGZY8bvJRvCMc4wL8j9ZBNJIhO0EmfJoxA6jDHDdfEwOaO1EJyUfJP8-DAa6K37gj5e7PavkbEBVADULN6AQ9ah7cE6laKdV05Dii7BD8rdpuhqVn2Ed2pSLkXXk7IRbpydwaD30dCMQ4qUM3dv17OaIaB29Gg-AJrA29GgGJ7_-v6TxmSPkwet6gM8OeF5crN783n7Ntt_urzaXuwzXTI-Z9DURSFYzXmroWxrUgmmOCvjMQ0nLVOYqaJqecEqpjlrqhqzkirR0sJo3bDzhBx9dVi09KDBazXLUdm_w3oprqhkZYVJHTUvjprJj18XCLMcbNDQ98rBuITILRmtOK9IpD7_h9qNi3dxI0kJI4KRkq6G9BTCjyF4aOXk7aD8rSRYru3KTq7tyrVdiUsZ242iZyfrpRnA_JHc1RkJr44EiP_3zYKXQVuIvRkbV5ulGe3__H8DzVayPA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2131831529</pqid></control><display><type>article</type><title>Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030</title><source>Elsevier ScienceDirect Journals</source><source>Recercat</source><creator>Estes, Chris ; Anstee, Quentin M. ; Arias-Loste, Maria Teresa ; Bantel, Heike ; Bellentani, Stefano ; Caballeria, Joan ; Colombo, Massimo ; Craxi, Antonio ; Crespo, Javier ; Day, Christopher P. ; Eguchi, Yuichiro ; Geier, Andreas ; Kondili, Loreta A. ; Kroy, Daniela C. ; Lazarus, Jeffrey V. ; Loomba, Rohit ; Manns, Michael P. ; Marchesini, Giulio ; Nakajima, Atsushi ; Negro, Francesco ; Petta, Salvatore ; Ratziu, Vlad ; Romero-Gomez, Manuel ; Sanyal, Arun ; Schattenberg, Jörn M. ; Tacke, Frank ; Tanaka, Junko ; Trautwein, Christian ; Wei, Lai ; Zeuzem, Stefan ; Razavi, Homie</creator><creatorcontrib>Estes, Chris ; Anstee, Quentin M. ; Arias-Loste, Maria Teresa ; Bantel, Heike ; Bellentani, Stefano ; Caballeria, Joan ; Colombo, Massimo ; Craxi, Antonio ; Crespo, Javier ; Day, Christopher P. ; Eguchi, Yuichiro ; Geier, Andreas ; Kondili, Loreta A. ; Kroy, Daniela C. ; Lazarus, Jeffrey V. ; Loomba, Rohit ; Manns, Michael P. ; Marchesini, Giulio ; Nakajima, Atsushi ; Negro, Francesco ; Petta, Salvatore ; Ratziu, Vlad ; Romero-Gomez, Manuel ; Sanyal, Arun ; Schattenberg, Jörn M. ; Tacke, Frank ; Tanaka, Junko ; Trautwein, Christian ; Wei, Lai ; Zeuzem, Stefan ; Razavi, Homie</creatorcontrib><description>[Display omitted] •Fatty liver disease is a growing cause of cirrhosis and liver cancer globally.•Disease burden is expected to increase with the epidemics of obesity and diabetes.•Modeling shows slow growth in total cases and greater increase in advanced cases.•Mortality and advanced liver disease will more than double during 2016–2030. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2018.05.036</identifier><identifier>PMID: 29886156</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aging ; Burden of disease ; Cardiovascular disease ; Cirrhosis ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Epidemics ; Fatty liver ; HCC ; Health care resource utilization ; Hepatocellular carcinoma ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Malalties del fetge ; Mathematical models ; Metabolic syndrome ; Models matemàtics ; Mortality ; NAFLD ; NASH ; Obesity ; Public health ; Urbanization</subject><ispartof>Journal of hepatology, 2018-10, Vol.69 (4), p.896-904</ispartof><rights>2018 European Association for the Study of the Liver</rights><rights>Copyright © 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Oct 2018</rights><rights>cc by-nc-nd (c) European Association for the Study of the Liver, 2018 info:eu-repo/semantics/openAccess &lt;a href="http://creativecommons.org/licenses/by-nc-nd/3.0/es/"&gt;http://creativecommons.org/licenses/by-nc-nd/3.0/es/&lt;/a&gt;</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-eb94483966fce5f91783a635635db61f3a03a47f64373c63b790352a8f24dccb3</citedby><cites>FETCH-LOGICAL-c536t-eb94483966fce5f91783a635635db61f3a03a47f64373c63b790352a8f24dccb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827818321214$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3536,26953,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29886156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Estes, Chris</creatorcontrib><creatorcontrib>Anstee, Quentin M.</creatorcontrib><creatorcontrib>Arias-Loste, Maria Teresa</creatorcontrib><creatorcontrib>Bantel, Heike</creatorcontrib><creatorcontrib>Bellentani, Stefano</creatorcontrib><creatorcontrib>Caballeria, Joan</creatorcontrib><creatorcontrib>Colombo, Massimo</creatorcontrib><creatorcontrib>Craxi, Antonio</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><creatorcontrib>Day, Christopher P.</creatorcontrib><creatorcontrib>Eguchi, Yuichiro</creatorcontrib><creatorcontrib>Geier, Andreas</creatorcontrib><creatorcontrib>Kondili, Loreta A.</creatorcontrib><creatorcontrib>Kroy, Daniela C.</creatorcontrib><creatorcontrib>Lazarus, Jeffrey V.</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Marchesini, Giulio</creatorcontrib><creatorcontrib>Nakajima, Atsushi</creatorcontrib><creatorcontrib>Negro, Francesco</creatorcontrib><creatorcontrib>Petta, Salvatore</creatorcontrib><creatorcontrib>Ratziu, Vlad</creatorcontrib><creatorcontrib>Romero-Gomez, Manuel</creatorcontrib><creatorcontrib>Sanyal, Arun</creatorcontrib><creatorcontrib>Schattenberg, Jörn M.</creatorcontrib><creatorcontrib>Tacke, Frank</creatorcontrib><creatorcontrib>Tanaka, Junko</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><creatorcontrib>Wei, Lai</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Razavi, Homie</creatorcontrib><title>Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>[Display omitted] •Fatty liver disease is a growing cause of cirrhosis and liver cancer globally.•Disease burden is expected to increase with the epidemics of obesity and diabetes.•Modeling shows slow growth in total cases and greater increase in advanced cases.•Mortality and advanced liver disease will more than double during 2016–2030. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.</description><subject>Aging</subject><subject>Burden of disease</subject><subject>Cardiovascular disease</subject><subject>Cirrhosis</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Epidemics</subject><subject>Fatty liver</subject><subject>HCC</subject><subject>Health care resource utilization</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Malalties del fetge</subject><subject>Mathematical models</subject><subject>Metabolic syndrome</subject><subject>Models matemàtics</subject><subject>Mortality</subject><subject>NAFLD</subject><subject>NASH</subject><subject>Obesity</subject><subject>Public health</subject><subject>Urbanization</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>XX2</sourceid><recordid>eNp9Ub2O1DAYjBCIWw5egAJZoqFIgn8Sx5FoTgt7HCxQHFdbjv2FdZQ4wU6QrqOm5Q15EhztHkgUSLZGnzUzms-TJE8Jzgkm_GWXdweYcoqJyHGZY8bvJRvCMc4wL8j9ZBNJIhO0EmfJoxA6jDHDdfEwOaO1EJyUfJP8-DAa6K37gj5e7PavkbEBVADULN6AQ9ah7cE6laKdV05Dii7BD8rdpuhqVn2Ed2pSLkXXk7IRbpydwaD30dCMQ4qUM3dv17OaIaB29Gg-AJrA29GgGJ7_-v6TxmSPkwet6gM8OeF5crN783n7Ntt_urzaXuwzXTI-Z9DURSFYzXmroWxrUgmmOCvjMQ0nLVOYqaJqecEqpjlrqhqzkirR0sJo3bDzhBx9dVi09KDBazXLUdm_w3oprqhkZYVJHTUvjprJj18XCLMcbNDQ98rBuITILRmtOK9IpD7_h9qNi3dxI0kJI4KRkq6G9BTCjyF4aOXk7aD8rSRYru3KTq7tyrVdiUsZ242iZyfrpRnA_JHc1RkJr44EiP_3zYKXQVuIvRkbV5ulGe3__H8DzVayPA</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Estes, Chris</creator><creator>Anstee, Quentin M.</creator><creator>Arias-Loste, Maria Teresa</creator><creator>Bantel, Heike</creator><creator>Bellentani, Stefano</creator><creator>Caballeria, Joan</creator><creator>Colombo, Massimo</creator><creator>Craxi, Antonio</creator><creator>Crespo, Javier</creator><creator>Day, Christopher P.</creator><creator>Eguchi, Yuichiro</creator><creator>Geier, Andreas</creator><creator>Kondili, Loreta A.</creator><creator>Kroy, Daniela C.</creator><creator>Lazarus, Jeffrey V.</creator><creator>Loomba, Rohit</creator><creator>Manns, Michael P.</creator><creator>Marchesini, Giulio</creator><creator>Nakajima, Atsushi</creator><creator>Negro, Francesco</creator><creator>Petta, Salvatore</creator><creator>Ratziu, Vlad</creator><creator>Romero-Gomez, Manuel</creator><creator>Sanyal, Arun</creator><creator>Schattenberg, Jörn M.</creator><creator>Tacke, Frank</creator><creator>Tanaka, Junko</creator><creator>Trautwein, Christian</creator><creator>Wei, Lai</creator><creator>Zeuzem, Stefan</creator><creator>Razavi, Homie</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><general>Elsevier B. V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>XX2</scope></search><sort><creationdate>201810</creationdate><title>Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030</title><author>Estes, Chris ; Anstee, Quentin M. ; Arias-Loste, Maria Teresa ; Bantel, Heike ; Bellentani, Stefano ; Caballeria, Joan ; Colombo, Massimo ; Craxi, Antonio ; Crespo, Javier ; Day, Christopher P. ; Eguchi, Yuichiro ; Geier, Andreas ; Kondili, Loreta A. ; Kroy, Daniela C. ; Lazarus, Jeffrey V. ; Loomba, Rohit ; Manns, Michael P. ; Marchesini, Giulio ; Nakajima, Atsushi ; Negro, Francesco ; Petta, Salvatore ; Ratziu, Vlad ; Romero-Gomez, Manuel ; Sanyal, Arun ; Schattenberg, Jörn M. ; Tacke, Frank ; Tanaka, Junko ; Trautwein, Christian ; Wei, Lai ; Zeuzem, Stefan ; Razavi, Homie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-eb94483966fce5f91783a635635db61f3a03a47f64373c63b790352a8f24dccb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aging</topic><topic>Burden of disease</topic><topic>Cardiovascular disease</topic><topic>Cirrhosis</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Epidemics</topic><topic>Fatty liver</topic><topic>HCC</topic><topic>Health care resource utilization</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Malalties del fetge</topic><topic>Mathematical models</topic><topic>Metabolic syndrome</topic><topic>Models matemàtics</topic><topic>Mortality</topic><topic>NAFLD</topic><topic>NASH</topic><topic>Obesity</topic><topic>Public health</topic><topic>Urbanization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Estes, Chris</creatorcontrib><creatorcontrib>Anstee, Quentin M.</creatorcontrib><creatorcontrib>Arias-Loste, Maria Teresa</creatorcontrib><creatorcontrib>Bantel, Heike</creatorcontrib><creatorcontrib>Bellentani, Stefano</creatorcontrib><creatorcontrib>Caballeria, Joan</creatorcontrib><creatorcontrib>Colombo, Massimo</creatorcontrib><creatorcontrib>Craxi, Antonio</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><creatorcontrib>Day, Christopher P.</creatorcontrib><creatorcontrib>Eguchi, Yuichiro</creatorcontrib><creatorcontrib>Geier, Andreas</creatorcontrib><creatorcontrib>Kondili, Loreta A.</creatorcontrib><creatorcontrib>Kroy, Daniela C.</creatorcontrib><creatorcontrib>Lazarus, Jeffrey V.</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Manns, Michael P.</creatorcontrib><creatorcontrib>Marchesini, Giulio</creatorcontrib><creatorcontrib>Nakajima, Atsushi</creatorcontrib><creatorcontrib>Negro, Francesco</creatorcontrib><creatorcontrib>Petta, Salvatore</creatorcontrib><creatorcontrib>Ratziu, Vlad</creatorcontrib><creatorcontrib>Romero-Gomez, Manuel</creatorcontrib><creatorcontrib>Sanyal, Arun</creatorcontrib><creatorcontrib>Schattenberg, Jörn M.</creatorcontrib><creatorcontrib>Tacke, Frank</creatorcontrib><creatorcontrib>Tanaka, Junko</creatorcontrib><creatorcontrib>Trautwein, Christian</creatorcontrib><creatorcontrib>Wei, Lai</creatorcontrib><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Razavi, Homie</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Recercat</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Estes, Chris</au><au>Anstee, Quentin M.</au><au>Arias-Loste, Maria Teresa</au><au>Bantel, Heike</au><au>Bellentani, Stefano</au><au>Caballeria, Joan</au><au>Colombo, Massimo</au><au>Craxi, Antonio</au><au>Crespo, Javier</au><au>Day, Christopher P.</au><au>Eguchi, Yuichiro</au><au>Geier, Andreas</au><au>Kondili, Loreta A.</au><au>Kroy, Daniela C.</au><au>Lazarus, Jeffrey V.</au><au>Loomba, Rohit</au><au>Manns, Michael P.</au><au>Marchesini, Giulio</au><au>Nakajima, Atsushi</au><au>Negro, Francesco</au><au>Petta, Salvatore</au><au>Ratziu, Vlad</au><au>Romero-Gomez, Manuel</au><au>Sanyal, Arun</au><au>Schattenberg, Jörn M.</au><au>Tacke, Frank</au><au>Tanaka, Junko</au><au>Trautwein, Christian</au><au>Wei, Lai</au><au>Zeuzem, Stefan</au><au>Razavi, Homie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>69</volume><issue>4</issue><spage>896</spage><epage>904</epage><pages>896-904</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><abstract>[Display omitted] •Fatty liver disease is a growing cause of cirrhosis and liver cancer globally.•Disease burden is expected to increase with the epidemics of obesity and diabetes.•Modeling shows slow growth in total cases and greater increase in advanced cases.•Mortality and advanced liver disease will more than double during 2016–2030. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population. NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29886156</pmid><doi>10.1016/j.jhep.2018.05.036</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-8278
ispartof Journal of hepatology, 2018-10, Vol.69 (4), p.896-904
issn 0168-8278
1600-0641
language eng
recordid cdi_csuc_recercat_oai_recercat_cat_2072_357019
source Elsevier ScienceDirect Journals; Recercat
subjects Aging
Burden of disease
Cardiovascular disease
Cirrhosis
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Epidemics
Fatty liver
HCC
Health care resource utilization
Hepatocellular carcinoma
Liver cancer
Liver cirrhosis
Liver diseases
Malalties del fetge
Mathematical models
Metabolic syndrome
Models matemàtics
Mortality
NAFLD
NASH
Obesity
Public health
Urbanization
title Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T01%3A47%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_csuc_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modeling%20NAFLD%20disease%20burden%20in%20China,%20France,%20Germany,%20Italy,%20Japan,%20Spain,%20United%20Kingdom,%20and%20United%20States%20for%20the%20period%202016%E2%80%932030&rft.jtitle=Journal%20of%20hepatology&rft.au=Estes,%20Chris&rft.date=2018-10&rft.volume=69&rft.issue=4&rft.spage=896&rft.epage=904&rft.pages=896-904&rft.issn=0168-8278&rft.eissn=1600-0641&rft_id=info:doi/10.1016/j.jhep.2018.05.036&rft_dat=%3Cproquest_csuc_%3E2131831529%3C/proquest_csuc_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2131831529&rft_id=info:pmid/29886156&rft_els_id=S0168827818321214&rfr_iscdi=true